Please ensure Javascript is enabled for purposes of website accessibility

Why Cardiovascular Systems Is Down Today

By Prosper Junior Bakiny – Jun 10, 2020 at 1:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market is reacting to the company's decision to initiate a public offering of common stock.

What happened?

Shares of Cardiovascular Systems (CSII 2.34%) are down by 10.2% as of 1:00 p.m. EDT on Wednesday after the company announced the pricing of a public offering of common stock on Tuesday evening. Investors aren't thrilled about the prospect of the medical device company diluting existing shareholders. 

So what

Shares of Cardiovascular Systems were worth a little under $38.50 apiece at the close of market on Tuesday. However, the company announced a public offering of 3,676,471 shares of its common stock for $34 per share. Also, Cardiovascular Systems is giving underwriters the option to purchase an additional 551,470 shares within 30 days. The company is expecting to raise about $125 million from this round of fundraising, which Cardiovascular Systems expects to close on Jun. 12.

Cardiovascular Systems will use the proceeds from this public offering of common stock for "working capital and general corporate purposes," including international expansion, product development, working capital, and more.

Man standing on a downward pointing arrow looking down.

Image Source: Getty Images.

 

Now what

Like many other medical device companies, Cardiovascular Systems has been hit hard amid the ongoing public health crisis. In the press release announcing its financial results for its latest reported quarter, Q3 2020, Cardiovascular Systems said: "Healthcare system response to COVID-19 pandemic delayed atherectomy procedures and negatively impacted third quarter results." During this quarter, Cardiovascular Systems reported revenue of $61.2 million, a 3.4% year over year decrease. Also, the healthcare company recorded a net loss per share of $0.08 after reporting net earnings per share of $0.02 during the prior-year quarter. 

Despite its poor financial results during the third quarter, Cardiovascular Systems seemed to be in a strong financial position, as the company had "cash and marketable securities totaling $107.3 million and no outstanding long-term debt" as of March 31.

During Cardiovascular Systems' third-quarter earnings conference call, the company's CEO, Scott Ward, said:

With a solid balance sheet, access to capital, no long-term debt, and strong gross margins, we will persevere through this pandemic and resume our double-digit growth trajectory when COVID-19 subsides and the healthcare system recovers.

Given this factor, Cardiovascular Systems' decision to raise funds by way of a public offering of common stock may have come as a bit of a surprise to investors.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cardiovascular Systems, Inc. Stock Quote
Cardiovascular Systems, Inc.
CSII
$14.43 (2.34%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.